FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
Publishing timestamp: 2024-06-17 19:02:51
Summary
The FDA approved Merck's new vaccine, Capvaxive, designed to protect adults from pneumococcus bacteria that can cause pneumonia. Analysts see this as a key growth driver for Merck as it prepares for losses from its cancer drug Keytruda. The vaccine aims to provide broader protection than others on the market and could potentially capture a majority of the market share among adults.
Sentiment: POSITIVE
Tickers: PFE, SAN-FR, MRK, GSK-GB, GSK, PCVX,
Keywords: pfizer inc, biotech and pharmaceuticals, business news, biotechnology, science, vaxcyte inc, gsk plc, merck & co inc, breaking news, health care industry, sanofi sa, pharmaceuticals, business,